Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Open accessAbstract
Glioblastomas are the most common form of malignant primary brain tumor and an important cause of morbidity and mortality. In recent years there have been important advances in understanding the molecular pathogenesis and biology of these tumors, but this has not translated into significantly improved outcomes for patients. In this consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of isocitrate dehydrogenase wildtype (IDHwt) glioblastomas will be discussed. In addition, novel therapies such as targeted molecular therapies, agents targeting DNA damage response and metabolism, immunotherapies, and viral therapies will be reviewed, as well as the current challenges and future directions for research.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
For HLA-A*02:01-positive patients with surgically resected MGMT-unmethylated GBM following standard of care, there is currently no efficacious treatment option available.
“For this patient population, there is currently no efficacious treatment option available [4].”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [4]
The Predictive Biomarkers section says temozolomide has little or no benefit in MGMT-unmethylated glioblastoma. The Recurrent Glioblastoma section says there is no clear standard-of-care salvage therapy and that listed options have not prolonged survival in randomized trials. Neither passage establishes that no efficacious treatment exists specifically for HLA-A*02:01-positive, surgically resected patients following standard care. (LLM, conf=0.84)
Experimental — accuracy not yet measuredThe current standard of care for GBM includes surgical resection and post-surgery radiotherapy with or without temozolomide chemotherapy.
“The current standard of care for GBM includes surgical resection and post-surgery radiotherapy with or without temozolomide (TMZ) chemotherapy [4, 5].”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [4]
Despite standard of care treatment, GBM recurrence is inevitable and there is no agreed salvage therapy post-recurrence.
“Despite standard of care treatment, GBM recurrence is inevitable and there is no agreed salvage therapy post-recurrence [4, 5].”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807 · see citing works
Self-citationThe 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D. F., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,672 · see citing works
Ostrom, Q. T., Gittleman, H. R., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C. A., & Barnholtz‐Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 12,049 · see citing works
Self-citationComprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735 · see citing works
Self-citationStupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., TAPHOORN, M. J. B., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Bélanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,667 · see citing works
Self-citation<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405 · see citing works
Self-citationCancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · see citing works
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,397 · see citing works
Macrophage activation and polarization: nomenclature and experimental guidelines
Murray, P. J., Allen, J. E., Biswas, S. K., Fisher, E. A., Gilroy, D. W., Goerdt, S., Gordon, S., Hamilton, J. A., Ivashkiv, L. B., Lawrence, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.008 · Cited by 6,337 · see citing works
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · see citing works
<i>IDH1</i> and <i>IDH2</i> Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847 · see citing works
Self-citationSingle-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063 · see citing works
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016 · see citing works
Self-citationImmunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,025 · see citing works
Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J. F., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,814 · see citing works
Self-citationStummer, W., Pichlmeier, U., Meinel, T., Wiestler, O. D., Zanella, F., & Reulen, H.-J. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70665-9 · Cited by 3,423 · see citing works
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834 · see citing works
Self-citationAn Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma
Neftel, C., Laffy, J., Filbin, M. G., Hara, T., Shore, M. E., Rahme, G. J., Richman, A. R., Silverbush, D., Shaw, M. L., Hebert, C. M., et al. (2019) · Cell · doi:10.1016/j.cell.2019.06.024 · Cited by 2,781 · see citing works
Self-citationTalimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Andtbacka, R. H. I., Kaufman, H. L., Collichio, F. A., AMATRUDA, T. T., Senzer, N. N., Chesney, J. A., Delman, K. A., S̄pitler, L. E., Puzanov, I. J., Agarwala, S. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3377 · Cited by 2,646 · see citing works
Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D. M., Lhermitte, B., Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., et al. (2017) · JAMA · doi:10.1001/jama.2017.18718 · Cited by 2,644 · see citing works
Self-citationDNA methylation-based classification of central nervous system tumours
Capper, D., Jones, D. T. W., Sill, M., Hovestadt, V., Schrimpf, D., Sturm, D., Koelsche, C., Sahm, F., Chavez, L., Reuss, D., et al. (2018) · Nature · doi:10.1038/nature26000 · Cited by 2,613 · see citing works
Self-citationOstrom, Q. T., Cioffi, G., Gittleman, H. R., Patil, N. T., Waite, K. A., Kruchko, C. A., & Barnholtz‐Sloan, J. S. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz150 · Cited by 2,598 · see citing works
Self-citationBevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Chinot, O. L., Wick, W., Mason, W. P., Henriksson, R., Saran, F. H., Nishikawa, R., Carpentier, A. F., Hoang‐Xuan, K., Kavan, P., Cernea, D. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308345 · Cited by 2,565 · see citing works
Self-citationLee, A. Y. Y., Levine, M. N., Baker, R. I., Bowden, C., Kakkar, A. K., Prins, M. H., Rickles, F. R., Julian, J. A., Haley, S., Kovacs, M. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025313 · Cited by 2,528 · see citing works
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N. A., Nicholas, M. K., Jensen, R. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,463 · see citing works
Self-citationCeccarelli, M., Barthel, F. P., Malta, T. M., Sabedot, T. S., Salama, S. R., Murray, B. A., Morozova, O., Newton, Y., Radenbaugh, A., Pagnotta, S. M., et al. (2016) · Cell · doi:10.1016/j.cell.2015.12.028 · Cited by 2,200 · see citing works
Self-citationNeoadjuvant PD-1 Blockade in Resectable Lung Cancer
Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099 · see citing works
A restricted cell population propagates glioblastoma growth after chemotherapy
Chen, J., Li, Y., Yu, T.-S., McKay, R. M., Burns, D. K., Kernie, S. G., & Parada, L. F. (2012) · Nature · doi:10.1038/nature11287 · Cited by 2,096 · see citing works
Wang, Q., Hu, B., Hu, X., Kim, H., Squatrito, M., Scarpace, L. M., deCarvalho, A. C., Lyu, S., Li, P., Li, Y., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.003 · Cited by 1,975 · see citing works
Self-citationCancer: Principles and Practice of Oncology.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-506_5 · Cited by 1,913 · see citing works
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610497 · Cited by 1,842 · see citing works
The blood–brain barrier and blood–tumour barrier in brain tumours and metastases
Arvanitis, C., Ferraro, G. B., & Jain, R. K. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0205-x · Cited by 1,834 · see citing works
Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D.-A., Jones, D. T. W., Konermann, C., Pfaff, E., Tönjes, M., Sill, M., Bender, S., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.024 · Cited by 1,828 · see citing works
Self-citationO’Rourke, D. M., Nasrallah, M. P., Desai, A. S., Melenhorst, J. J., Mansfield, K. G., Morrissette, J. J. D., Martinez‐Lage, M., Brem, S. S., Maloney, E., Shen, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa0984 · Cited by 1,812 · see citing works
Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics
Sottoriva, A., Spiteri, I., Piccirillo, S. G. M., Touloumis, A., Collins, V. P., Marioni, J. C., Curtis, C., Watts, C., & Tavaré, S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219747110 · Cited by 1,737 · see citing works
An extent of resection threshold for newly diagnosed glioblastomas
Sanai, N., Polley, M. C., McDermott, M. W., Parsa, A. T., & Berger, M. S. (2011) · Journal of neurosurgery · doi:10.3171/2011.2.jns10998 · Cited by 1,650 · see citing works
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Raskob, G. E., van Es, N., Verhamme, P. B., Carrier, M., Nisio, M. D., Garcia, D. A., GROSSO, M. A., Kakkar, A. K., Kovacs, M. J., Mercuri, M. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1711948 · Cited by 1,633 · see citing works
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
Platten, M., Nollen, E. A. A., Röhrig, U. F., Fallarino, F., & Opitz, C. A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0016-5 · Cited by 1,586 · see citing works
Self-citationOncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.027 · Cited by 1,520 · see citing works
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma
Reardon, D. A., Brandes, A. A., Omuro, A. M. P., Mulholland, P. J., Lim, M. K., Wick, A., Baehring, J. M., Ahluwalia, M. S., Roth, P., Bähr, O., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.1024 · Cited by 1,514 · see citing works
Self-citationNeoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., Mathewson, N. D., Li, S., Oliveira, G., Giobbie-Hurder, A., Felt, K., Gjini, E., et al. (2019) · Nature · doi:10.1038/s41586-018-0792-9 · Cited by 1,432 · see citing works
Self-citationBrem, H., Piantadosi, S., Burger, P. C., Walker, M., Selker, R. G., Vick, N. A., Black, K. L., Sisti, M. B., Brem, S. S., Mohr, G., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90755-6 · Cited by 1,390 · see citing works
Cloughesy, T. F., Mochizuki, A. Y., Orpilla, J. R., Hugo, W., Lee, A. H., Davidson, T. B., Wang, A. C., Ellingson, B. M., Rytlewski, J. A., Sanders, C. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0337-7 · Cited by 1,382 · see citing works
Self-citationCurrent state of immunotherapy for glioblastoma
Lim, M. K., Xia, Y., Bettegowda, C., & Weller, M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0003-5 · Cited by 1,373 · see citing works
Self-citationKillela, P. J., Reitman, Z. J., Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L. A., Friedman, A. H., Friedman, H., Gallia, G. L., Giovanella, B. C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303607110 · Cited by 1,368 · see citing works
Electrical and synaptic integration of glioma into neural circuits
Venkatesh, H. S., Morishita, W., Geraghty, A. C., Silverbush, D., Gillespie, S. M., Arzt, M., Tam, L. T., Espenel, C., Ponnuswami, A., Ni, L., et al. (2019) · Nature · doi:10.1038/s41586-019-1563-y · Cited by 1,366 · see citing works
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma
Johnson, B. E., Mazor, T., Hong, C., Barnes, M., Aihara, K., McLean, C. Y., Fouse, S. D., Yamamoto, S., Ueda, H., Tatsuno, K., et al. (2014) · Science · doi:10.1126/science.1239947 · Cited by 1,362 · see citing works
Self-citationYoung, A., Marshall, A., Thirlwall, J., Chapman, O., Lokare, A., Hill, C. S., Hale, D., Dunn, J., Lyman, G. H., Hutchinson, C. E., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.8034 · Cited by 1,359 · see citing works
Westphal, M., Hilt, D. C., Bortey, E. B., Delavault, P., Olivares, R., Warnke, P. C., Whittle, I. R., Jääskeläinen, J. E., & Ram, Z. (2003) · Neuro-Oncology · doi:10.1093/neuonc/5.2.79 · Cited by 1,331 · see citing works
Malmström, A., Grønberg, B. H., Marosi, C., Stupp, R., Frappaz, D., Schultz, H., Abacıoğlu, U., Tavelin, B., Lhermitte, B., Hegi, M. E., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70265-6 · Cited by 1,282 · see citing works
Self-citationGlutamatergic synaptic input to glioma cells drives brain tumour progression
Venkataramani, V., Tanev, D. I., Strahle, C., Studier-Fischer, A., Fankhauser, L., Kessler, T., Körber, C., Kardorff, M., Ratliff, M., Xie, R., et al. (2019) · Nature · doi:10.1038/s41586-019-1564-x · Cited by 1,197 · see citing works
Self-citationState-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189 · see citing works
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
Perry, J., Laperrière, N., O'Callaghan, C. J., Brandes, A. A., Menten, J. J., Phillips, C., Fay, M. F., Nishikawa, R., Cairncross, J. G., Roa, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611977 · Cited by 1,179 · see citing works
Self-citationSugahara, T., Korogi, Y., Kochi, M., Ikushima, I., Shigematu, Y., Hirai, T., Okuda, T., Liang, L., Ge, Y., Komohara, Y., et al. (1999) · Journal of Magnetic Resonance Imaging · doi:10.1002/(sici)1522-2586(199901)9:1 · Cited by 1,151 · see citing works
Weller, M., Butowski, N. A., Tran, D. D., Recht, L. D., Lim, M. K., Hirte, H. W., Ashby, L. S., Mechtler, L. L., Goldlust, S. A., IWAMOTO, F. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30517-x · Cited by 1,138 · see citing works
Self-citationLe Tourneau, C., Delord, J.-P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., Campone, M., Trédan, O., Massiani, M.-A., Mauborgne, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00188-6 · Cited by 1,137 · see citing works
Wick, W., Platten, M., Meisner, C., Felsberg, J., Tabatabai, G., Simon, M., Nikkhah, G., Papsdorf, K., Steinbach, J. P., Sabel, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70164-x · Cited by 1,136 · see citing works
Self-citationWeller, M., van den Bent, M. J., Tonn, J. C., Stupp, R., Preusser, M., Moyal, E. C., Henriksson, R., Rhun, É. L., Balañá, C., Chinot, O. L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30194-8 · Cited by 1,094 · see citing works
Self-citationAssociation of the Extent of Resection With Survival in Glioblastoma
Brown, T. J., Brennan, M., Li, M. J., Church, E. W., Brandmeir, N. J., Rakszawski, K. L., Patel, A. S., Rizk, E., Suki, D., Sawaya, R. A., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1373 · Cited by 1,087 · see citing works
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Gilbert, M. R., Wang, M., Aldape, K. D., Stupp, R., Hegi, M. E., Jaeckle, K. A., Armstrong, T. S., Wefel, J. S., Won, M., Blumenthal, D. T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.6968 · Cited by 1,063 · see citing works
Self-citationStupp, R., Hegi, M. E., Gorlia, T., Erridge, S. C., Perry, J., Hong, Y.-K., Aldape, K. D., Lhermitte, B., Pietsch, T., Grujicic, D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70379-1 · Cited by 1,052 · see citing works
Self-citationImpact of Intraoperative Stimulation Brain Mapping on Glioma Surgery Outcome: A Meta-Analysis
Hamer, P. C. D. W., Robles, S. G., Zwinderman, A. H., Duffau, H., & Berger, M. S. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4818 · Cited by 1,046 · see citing works
Lomustine and Bevacizumab in Progressive Glioblastoma
Wick, W., Gorlia, T., Bendszus, M., TAPHOORN, M. J. B., Sahm, F., Harting, I., Brandes, A. A., Taal, W., Dômont, J., Idbaïh, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707358 · Cited by 972 · see citing works
Self-citationCoactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., Stegh, A. H., Bradner, J. E., Ligon, K. L., Brennan, C., et al. (2007) · Science · doi:10.1126/science.1142946 · Cited by 938 · see citing works
Actively personalized vaccination trial for newly diagnosed glioblastoma
Hilf, N., Kuttruff-Coqui, S., Frenzel, K., Bukur, V., Stevanović, S., Gouttefangeas, C., Platten, M., Tabatabai, G., Dutoit, V., van der Burg, S. H., et al. (2019) · Nature · doi:10.1038/s41586-018-0810-y · Cited by 938 · see citing works
Self-citationRoa, W., Brasher, P. M. A., Bauman, G. S., Anthes, M., Bruera, E. D., Chan, A., Fisher, B., Fulton, D. S., Gulavita, S. P. P., Hao, C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.082 · Cited by 902 · see citing works
Brat, D. J., Aldape, K., Colman, H., Holland, E. C., Louis, D. N., Jenkins, R. B., Kleinschmidt-DeMasters, B. K., Perry, A., Reifenberger, G., Stupp, R., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1913-0 · Cited by 901 · see citing works
Self-citationZeng, J., See, A. P., Phallen, J., Jackson, C. M., Belcaid, Z., Ruzevick, J., Durham, N., Meyer, C., Harris, T. J., Albesiano, E., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.12.025 · Cited by 889 · see citing works
Self-citationStupp, R., Wong, E. T., Kanner, A. A., Steinberg, D., Engelhard, H., Heidecke, V., Kirson, E. D., Taillibert, S., Liebermann, F., Dbalý, V., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.04.011 · Cited by 862 · see citing works
Self-citationBouffet, E., Larouche, V., Campbell, B. B., Merico, D., de Borja, R., Aronson, M., Durno, C., Krueger, J., Cabric, V., Ramaswamy, V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.6552 · Cited by 857 · see citing works
Glantz, M., Cole, B. F., Forsyth, P. A., Recht, L. D., Wen, P. Y., Chamberlain, M. C., Grossman, S. A., & Cairncross, J. G. (2000) · Neurology · doi:10.1212/wnl.54.10.1886 · Cited by 856 · see citing works
Self-citationExtrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity
Turner, K. M., Deshpande, V., Beyter, D., Koga, T., Rusert, J. M., Lee, C., Li, B., Arden, K. C., Ren, B., Nathanson, D. A., et al. (2017) · Nature · doi:10.1038/nature21356 · Cited by 852 · see citing works
Self-citationNeoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Amaria, R. N., Reddy, S. M., Tawbi, H. A., Davies, M. A., Ross, M. I., Glitza, I. C., Cormier, J. N., Lewis, C., Hwu, W.-J., Hanna, E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0197-1 · Cited by 835 · see citing works
Recurrent Glioblastoma Treated with Recombinant Poliovirus
Desjardins, A., Gromeier, M., Herndon, J. E., Beaubier, N. T., Bolognesi, D. P., Friedman, A. H., Friedman, H. S., McSherry, F., Muscat, A. M., Nair, S. K., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716435 · Cited by 821 · see citing works
Alexander, B. M., & Cloughesy, T. F. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.0119 · Cited by 797 · see citing works
Self-citationImmunotherapy response assessment in neuro-oncology: a report of the RANO working group
Okada, H., Weller, M., Huang, R. Y., Finocchiaro, G., Gilbert, M. R., Wick, W., Ellingson, B. M., Hashimoto, N., Pollack, I. F., Brandes, A. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00088-1 · Cited by 788 · see citing works
Self-citationMechanisms of immunotherapy resistance: lessons from glioblastoma
Jackson, C. M., Choi, J. H., & Lim, M. K. (2019) · Nature Immunology · doi:10.1038/s41590-019-0433-y · Cited by 760 · see citing works
Self-citationTaal, W., Oosterkamp, H. M., Walenkamp, A., Dubbink, H. J., Beerepoot, L. V., Hanse, M. C. J., Buter, J., Honkoop, A. H., Boerman, D. H., Vos, F. D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70314-6 · Cited by 759 · see citing works
Self-citationClonal evolution of glioblastoma under therapy
Wang, J., Cazzato, E., Ladewig, E., Frattini, V., Rosenbloom, D. I. S., Zairis, S., Abate, F., Liu, Z., Elliott, O., Shin, Y., et al. (2016) · Nature Genetics · doi:10.1038/ng.3590 · Cited by 759 · see citing works
Sarkaria, J. N., Hu, L. S., Parney, I. F., Pafundi, D. H., Brinkmann, D. H., Laack, N. N., Giannini, C., Burns, T. C., Kizilbash, S. H., Laramy, J. K., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox175 · Cited by 746 · see citing works
Self-citationAlbert, N. L., Weller, M., Suchorska, B., Galldiks, N., Soffietti, R., Kim, M. M., la Fougère, C. J., Pope, W. B., Law, I. G., Arbizu, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now058 · Cited by 743 · see citing works
Self-citationBrain immunology and immunotherapy in brain tumours
Sampson, J. H., Gunn, M. D., Fecci, P. E., & Ashley, D. M. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0224-7 · Cited by 733 · see citing works
Levin, V. A., Bidaut, L. M., Hou, P., Kumar, A. J., Wefel, J. S., Bekele, B. N., Prabhu, S. S., Loghin, M. E., Gilbert, M. R., & Jackson, E. F. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.12.061 · Cited by 731 · see citing works
Self-citationLang, F. F., Conrad, C. A., Gomez‐Manzano, C., Yung, W. K. A., Sawaya, R. A., Weinberg, J. S., Prabhu, S. S., Rao, G., Fuller, G. N., Aldape, K., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.8219 · Cited by 718 · see citing works
Self-citationMosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma
Snuderl, M., Fazlollahi, L., Le, L. P., Nitta, M., Zhelyazkova, B. H., Davidson, C. J., Akhavanfard, S., Cahill, D. P., Aldape, K., Betensky, R. A., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.005 · Cited by 708 · see citing works
Self-citationTargeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA
Nathanson, D. A., Gini, B., Mottahedeh, J., Visnyei, K., Koga, T., Gomez, G. G., Eskin, A., Hwang, K., Wang, J., Masui, K., et al. (2013) · Science · doi:10.1126/science.1241328 · Cited by 699 · see citing works
Self-citationMolecular targeted therapy of glioblastoma
Rhun, É. L., Preusser, M., Roth, P., Reardon, D. A., van den Bent, M. J., Wen, P. Y., Reifenberger, G., & Weller, M. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101896 · Cited by 688 · see citing works
Self-citationConsensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials
Ellingson, B. M., Bendszus, M., Boxerman, J. L., Barboriak, D. P., Erickson, B. J., Smits, M., Nelson, S. J., Gerstner, E. R., Alexander, B. M., Goldmacher, G., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov095 · Cited by 681 · see citing works
Self-citationGuo, A. C., Cummings, T. J., Dash, R. C., & Provenzale, J. M. (2002) · Radiology · doi:10.1148/radiol.2241010637 · Cited by 681 · see citing works
Mechanisms and therapeutic implications of hypermutation in gliomas
Touat, M., Li, Y. Y., Boynton, A. N., Spurr, L. F., Iorgulescu, J. B., Bohrson, C. L., Cortés‐Ciriano, I., Birzu, C., Geduldig, J. E., Pelton, K., et al. (2020) · Nature · doi:10.1038/s41586-020-2209-9 · Cited by 672 · see citing works
Self-citationSequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors
Chongsathidkiet, P., Jackson, C., Koyama, S., Loebel, F., Cui, X., Farber, S. H., Woroniecka, K. I., Elsamadicy, A. A., Dechant, C. A., Kemeny, H. R., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0135-2 · Cited by 670 · see citing works
Laws, E. R., Parney, I. F., Huang, W., Anderson, F. A., Morris, A. M., Asher, A., Lillehei, K. O., Bernstein, M., Brem, H., Sloan, A. E., et al. (2003) · Journal of neurosurgery · doi:10.3171/jns.2003.99.3.0467 · Cited by 669 · see citing works
Self-citationClinical Proton MR Spectroscopy in Central Nervous System Disorders
Öz, G., Alger, J. R., Barker, P. B., Bartha, R., Bizzi, A., Boesch, C., Bolan, P. J., Brindle, K. M., Cudalbu, C., Di̇nçer, A., et al. (2014) · Radiology · doi:10.1148/radiol.13130531 · Cited by 663 · see citing works
Human glioblastoma arises from subventricular zone cells with low-level driver mutations
Lee, J. H., Lee, J. H., Kahng, J. Y., Kim, S. H., Park, J. S., Yoon, S. J., Um, J.-Y., Kim, W. K., Lee, J.-H., Park, J., et al. (2018) · Nature · doi:10.1038/s41586-018-0389-3 · Cited by 659 · see citing works
T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma
Woroniecka, K. I., Chongsathidkiet, P., Rhodin, K. E., Kemeny, H. R., Dechant, C. A., Farber, S. H., Elsamadicy, A. A., Cui, X., Koyama, S., Jackson, C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1846 · Cited by 651 · see citing works
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
Schalper, K. A., Rodriguez-Ruiz, M. E., Díez-Valle, R., López‐Janeiro, Á., Porciuncula, A., Idoate, M. A., Inogés, S., de Andrea, C., de Cerio, A. L.-D., Tejada, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0339-5 · Cited by 645 · see citing works
Stupp, R., Taillibert, S., Kanner, A. A., Read, W. L., Steinberg, D. M., Lhermitte, B., Toms, S. A., Idbaïh, A., Ahluwalia, M. S., Fink, K., et al. (2017) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) · doi:10.5167/uzh-143757 · Cited by 630 · see citing works
Self-citationTracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid
Miller, A. M., Shah, R. H., Pentsova, E. I., Pourmaleki, M., Briggs, S. R., DiStefano, N. M., Zheng, Y., Skakodub, A., Mehta, S. A., Campos, C., et al. (2019) · Nature · doi:10.1038/s41586-019-0882-3 · Cited by 624 · see citing works
Self-citationBatchelor, T. T., Mulholland, P. J., Neyns, B., Nabors, B., Campone, M., Wick, A., Mason, W. P., Mikkelsen, T., Phuphanich, S., Ashby, L. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.2464 · Cited by 610 · see citing works
Self-citationTaplitz, R. A., Kennedy, E. B., Bow, E. J., Crews, J. R., Gleason, C. L., Hawley, D. K., Langston, A. A., Nastoupil, L. J., Rajotte, M., Rolston, K. V. I., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00374 · Cited by 606 · see citing works
Oncolytic Viruses in Cancer Treatment
Lawler, S. E., Speranza, M. C., Cho, C., & Chiocca, E. A. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2064 · Cited by 602 · see citing works
Self-citationButowski, N. A., Colman, H., de Groot, J., Omuro, A. M. P., Nayak, L., Wen, P. Y., Cloughesy, T. F., Marimuthu, A., Haidar, S., Perry, A., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov245 · Cited by 593 · see citing works
Self-citationCloughesy, T. F., Yoshimoto, K., Nghiemphu, P., Brown, K., Dang, J., Zhu, S., Hsueh, T., Chen, Y., Wang, W., Youngkin, D., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050008 · Cited by 593 · see citing works
Self-citationMGMT testing—the challenges for biomarker-based glioma treatment
Wick, W., Weller, M., van den Bent, M. J., Sanson, M., Weiler, M., von Deimling, A., Plass, C., Hegi, M. E., Platten, M., & Reifenberger, G. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.100 · Cited by 580 · see citing works
Self-citationHerrlinger, U., Tzaridis, T., Mack, F., Steinbach, J. P., Schlegel, U. S., Sabel, M., Hau, P., Kortmann, R., Krex, D., Grauer, O. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31791-4 · Cited by 579 · see citing works
Self-citationGenomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
Rodon, J. A., Soria, J., Berger, R., Miller, W. H., Rubin, E., Kugel, A., Tsimberidou, A. M., Saintigny, P., Ackerstein, A., Braña, I., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0424-4 · Cited by 579 · see citing works
Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide
Grossman, S. A., Ye, X., Lesser, G. J., Sloan, A. E., Carraway, H. E., Desideri, S., & Piantadosi, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0774 · Cited by 574 · see citing works
van den Bent, M. J., Brandes, A. A., Rampling, R., Kouwenhoven, M. C. M., Kros, J. M., Carpentier, A. F., Clément, P. M., Frénay, M., Campone, M., Baurain, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5984 · Cited by 574 · see citing works
Self-citationWainwright, D. A., Chang, A. L., Dey, M., Balyasnikova, I. V., Kim, C. K., Tobias, A. L., Cheng, Y., Kim, J. W., Qiao, J., Zhang, L., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0514 · Cited by 571 · see citing works
Law, I. G., Albert, N. L., Arbizu, J., Boellaard, R., Drzezga, A. E., Galldiks, N., la Fougère, C. J., Langen, K., Lopci, E., Lowe, V. J., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4207-9 · Cited by 560 · see citing works
Self-citationLongitudinal molecular trajectories of diffuse glioma in adults
Barthel, F. P., Johnson, K. C., Varn, F. S., Moskalik, A. D., Tanner, G., Kocakavuk, E., Anderson, K. J., Abiola, O., Aldape, K., Alfaro-Munoz, K. D., et al. (2019) · Nature · doi:10.1038/s41586-019-1775-1 · Cited by 559 · see citing works
Self-citationPaediatric and adult glioblastoma: multiform (epi)genomic culprits emerge
Sturm, D., Bender, S., Jones, D. T. W., Lichter, P., Grill, J., Becher, O., Hawkins, C., Majewski, J., Jones, C., Costello, J. F., et al. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3655 · Cited by 555 · see citing works
Self-citationLiau, L. M., Ashkan, K., Tran, D. D., Campian, J. L., Trusheim, J. E., Cobbs, C., Heth, J., Salacz, M. E., Taylor, S. A., D’Andre, S. D., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1507-6 · Cited by 540 · see citing works
Self-citationGlioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancerPreprint
Gimple, R. C., Bhargava, S., Dixit, D., & Rich, J. N. (2019) · Genes & Development · doi:10.1101/gad.324301.119 · Cited by 539 · see citing works
Szerlip, N. J., Pedraza, A. M., Chakravarty, D., Azim, M., McGuire, J., Fang, Y., Ozawa, T., Holland, E. C., Huse, J. T., Jhanwar, S. C., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1114033109 · Cited by 538 · see citing works
Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance
Liau, B. B., Sievers, C., Donohue, L. K., Gillespie, S. M., Flavahan, W. A., Miller, T. E., Venteicher, A. S., Hebert, C. H., Carey, C. D., Rodig, S. J., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2016.11.003 · Cited by 535 · see citing works
Yan, H., Killela, P. J., Reitman, Z. J., Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L. A., Friedman, A. H., Friedman, H. S., Gallia, G. L., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou206.18 · Cited by 530 · see citing works
Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors
Capper, D., Weißert, S., Balß, J., Habel, A., Meyer, J., Jaeger, D., Ackermann, U., Tessmer, C., Korshunov, A., Zentgraf, H., et al. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00352.x · Cited by 523 · see citing works
cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas
Brat, D. J., Aldape, K., Colman, H., Figarella-Branger, D. F., Fuller, G. N., Giannini, C., Holland, E. C., Jenkins, R. B., Kleinschmidt-DeMasters, B. K., Komori, T., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02127-9 · Cited by 519 · see citing works
Self-citationWick, W., Puduvalli, V. K., Chamberlain, M. C., van den Bent, M. J., Carpentier, A. F., Cher, L., Mason, W. P., Weller, M., Hong, S., Musib, L. C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2595 · Cited by 518 · see citing works
Self-citationOvercoming therapeutic resistance in glioblastoma: the way forward
Osuka, S., & Meir, E. G. V. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89587 · Cited by 509 · see citing works
Law, M., Yang, S., Babb, J. S., Knopp, E. A., Golfinos, J. G., Zagzag, D., & Johnson, G. (2004) · PubMed Central · Cited by 508 · see citing works
Chaichana, K. L., Jusué-Torres, I., Navarro-Ramírez, R., Raza, S. M., Pascual-Gallego, M., Ibrahim, A., Hernandez-Hermann, M., Gomez, L., Ye, X., WEINGART, J. D., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not137 · Cited by 505 · see citing works
Self-citationModified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials
Ellingson, B. M., Wen, P. Y., & Cloughesy, T. F. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0507-6 · Cited by 481 · see citing works
Self-citationKickingereder, P., Isensee, F., Tursunova, I., Petersen, J., Neuberger, U., Bonekamp, D., Brugnara, G., Schell, M., Keßler, T., Foltyn‐Dumitru, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30098-1 · Cited by 459 · see citing works
Self-citationGenomic correlates of response to immune checkpoint blockade
Keenan, T. E., Burke, K. P., & Van Allen, E. M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0382-x · Cited by 448 · see citing works
Grabowski, M. M., Recinos, P. F., Nowacki, A. S., Schroeder, J. L., Angelov, L., Barnett, G. H., & Vogelbaum, M. A. (2014) · Journal of neurosurgery · doi:10.3171/2014.7.jns132449 · Cited by 435 · see citing works
Reardon, D. A., Gokhale, P. C., Klein, S. R., Ligon, K. L., Rodig, S. J., Ramkissoon, S. H., Jones, K. L., Conway, A. S., Liao, X., Zhou, J. M., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0151 · Cited by 433 · see citing works
Self-citationHunter, C., Smith, R., Cahill, D. P., Stephens, P., Stevens, C., Teague, J. W., Greenman, C., Edkins, S., Bignell, G. R., Davies, H. R., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0127 · Cited by 431 · see citing works
Self-citationResponse Assessment in Neuro-Oncology Clinical Trials
Wen, P. Y., Chang, S. M., van den Bent, M. J., Vogelbaum, M. A., Macdonald, D. R., & Lee, E. Q. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.7511 · Cited by 426 · see citing works
Self-citationLamborn, K. R., Yung, W. K. A., Chang, S. M., Wen, P. Y., Cloughesy, T. F., DeAngelis, L. M., Robins, H. I., Lieberman, F. S., Fine, H. A., Fink, K., et al. (2008) · Neuro-Oncology · doi:10.1215/15228517-2007-062 · Cited by 417 · see citing works
Self-citationKim, H., Zheng, S., Amini, S. S., Virk, S. M., Mikkelsen, T., Brat, D. J., Grimsby, J., Sougnez, C., Muller, F., Hu, J., et al. (2015) · Genome Research · doi:10.1101/gr.180612.114 · Cited by 411 · see citing works
Self-citationOncolytic Viruses and Their Application to Cancer Immunotherapy
Chiocca, E. A., & Rabkin, S. D. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0015 · Cited by 410 · see citing works
Self-citationCognitive Deficits before Treatment among Patients with Brain Tumors
Tucha, O. M., Smely, C., Preier, M., & Lange, K. W. (2000) · Neurosurgery · doi:10.1097/00006123-200008000-00011 · Cited by 399 · see citing works
Wei, J., Marisetty, A., Schrand, B., Gabrusiewicz, K. R., Hashimoto, Y., Ott, M., Grami, Z. A., Kong, L., Ling, X., Caruso, H. G., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121266 · Cited by 399 · see citing works
Self-citationLombardi, G., Salvo, G. L. D., Brandes, A. A., Eoli, M., Rudà, R., Faedi, M., Lolli, I. R., Pace, A., Daniele, B., Pasqualetti, F., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30675-2 · Cited by 397 · see citing works
Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy
Lan, X., Jörg, D. J., Cavalli, F. M. G., Richards, L. M., Nguyen, L. V., Vanner, R. J., Guilhamon, P., Lee, L., Kushida, M. M., Pellacani, D., et al. (2017) · Nature · doi:10.1038/nature23666 · Cited by 390 · see citing works
ESTRO-ACROP guideline “target delineation of glioblastomas”
Niyazi, M., Brada, M., Chalmers, A. J., Combs, S. E., Erridge, S., Fiorentino, A., Grosu, A., Lagerwaard, F. J., Minniti, G. C., Mirimanoff, R., et al. (2016) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.12.003 · Cited by 389 · see citing works
Self-citationPhase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
Perry, J., Bélanger, K., Mason, W. P., Fulton, D. S., Kavan, P., Easaw, J. C., Shields, C., Kirby, S., Macdonald, D., Eisenstat, D. D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5520 · Cited by 379 · see citing works
Higano, S., Yun, X., Kumabe, T., Watanabe, M., Mugikura, S., Umetsu, A., Sato, A., Yamada, T., & Takahashi, S. (2006) · Radiology · doi:10.1148/radiol.2413051276 · Cited by 374 · see citing works
Patterns of Care for Adults With Newly Diagnosed Malignant Glioma
Chang, S. M. (2005) · JAMA · doi:10.1001/jama.293.5.557 · Cited by 371 · see citing works
Self-citationIdbaïh, A., Canney, M. S., Belin, L., Desseaux, C., Vignot, A., Bouchoux, G., Asquier, N., Law-Ye, B., Leclercq, D., Bissery, A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3643 · Cited by 367 · see citing works
Self-citationCorticosteroids compromise survival in glioblastoma
Pitter, K. L., Tamagno, I., Alikhanyan, K., Hosni-Ahmed, A., Pattwell, S. S., Donnola, S. B., Dai, C. S., Ozawa, T., Chang, M., Chan, T. A.-T., et al. (2016) · Brain · doi:10.1093/brain/aww046 · Cited by 364 · see citing works
Self-citationDose‐effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors
Vecht, C. J., Hovestadt, A., Verbiest, H. B. C., van der Vliet, H. J., & van Putten, W. L. J. (1994) · Neurology · doi:10.1212/wnl.44.4.675 · Cited by 352 · see citing works
BRAF Inhibition in BRAF V600 -Mutant Gliomas: Results From the VE-BASKET Study
Kaley, T. J., Touat, M., Subbiah, V., Hollebecque, A., Rodon, J. A., Lockhart, A. C., Keedy, V. L., Bielle, F., Hofheinz, R., Joly, F., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9990 · Cited by 352 · see citing works
Altered cellular metabolism in gliomas — an emerging landscape of actionable co-dependency targets
Bi, J., Chowdhry, S., Wu, S., Zhang, W., Masui, K., & Mischel, P. S. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0226-5 · Cited by 348 · see citing works
Bady, P., Sciuscio, D., Diserens, A., Bloch, J., van den Bent, M. J., Marosi, C., Dietrich, P.-Y., Weller, M., Mariani, L., Heppner, F. L., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1016-2 · Cited by 345 · see citing works
Self-citationVivanco, I., Robins, H. I., Rohle, D., Campos, C., Grommes, C., Nghiemphu, P. L., Kubek, S., Oldrini, B., Chheda, M. G., Yannuzzi, N. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0284 · Cited by 343 · see citing works
Self-citationFecci, P. E., Ochiai, H., Mitchell, D. A., Grossi, P. M., Sweeney, A. E., Archer, G. E., Cummings, T. J., Allison, J. P., Bigner, D. D., & Sampson, J. H. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2070 · Cited by 343 · see citing works
Melin, B. S., Barnholtz‐Sloan, J. S., Wrensch, M., Johansen, C., Il’yasova, D., Kinnersley, B., Ostrom, Q. T., Labrèche, K., Chen, Y., Armstrong, G., et al. (2017) · Nature Genetics · doi:10.1038/ng.3823 · Cited by 343 · see citing works
Self-citationRoa, W., Kępka, L., Kumar, N., Sinaika, V., Matiello, J., Lomidze, D., Hentati, D., de Castro, D. G., Dyttus‐Cebulok, K., Drodge, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.6606 · Cited by 340 · see citing works
An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers
Villa, G. R., Hulce, J. J., Zanca, C., Bi, J., Ikegami, S., Cahill, G. L., Gu, Y., Lum, K. M., Masui, K., Yang, H., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.008 · Cited by 327 · see citing works
Self-citationWeller, M., Tabatabai, G., Kästner, B., Felsberg, J., Steinbach, J. P., Wick, A., Schnell, O., Hau, P., Herrlinger, U., Sabel, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2737 · Cited by 320 · see citing works
Self-citationRisk factors for childhood and adult primary brain tumors
Ostrom, Q. T., Fahmideh, M. A., Cote, D. J., Muskens, I. S., Schraw, J. M., Scheurer, M. E., & Bondy, M. L. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz123 · Cited by 314 · see citing works
Marko, N. F., Weil, R. J., Schroeder, J. L., Lang, F. F., Suki, D., & Sawaya, R. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.8886 · Cited by 311 · see citing works
CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges
Bagley, S. J., Desai, A. S., Linette, G. P., June, C. H., & O’Rourke, D. M. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy032 · Cited by 311 · see citing works
Pseudoprogression of brain tumors
Thust, S. C., van den Bent, M. J., & Smits, M. (2018) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.26171 · Cited by 308 · see citing works
European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma
Pace, A., Dirven, L., Koekkoek, J. A. F., Golla, H., Fleming, J., Rudà, R., Marosi, C., Rhun, É. L., Grant, R., Oliver, K. R., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30345-5 · Cited by 305 · see citing works
Self-citationdeCarvalho, A. C., Kim, H., Poisson, L., Winn, M. E., Mueller, C., Cherba, D., Koeman, J. M., Seth, S., Protopopov, A. I., Felicella, M. M., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0105-0 · Cited by 305 · see citing works
Self-citationStummer, W., Tonn, J., Mehdorn, H. M., Nestler, U., Franz, K., Goetz, C., Bink, A., & Pichlmeier, U. (2010) · Journal of neurosurgery · doi:10.3171/2010.3.jns097 · Cited by 304 · see citing works
Self-citationAnti–PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM
Mathios, D., Kim, J. E., Mangraviti, A., Phallen, J. A., Park, C., Jackson, C. M., Garzón-Muvdi, T., Kim, E. S., Theodros, D., Polanczyk, M. J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag2942 · Cited by 301 · see citing works
Self-citationTRK inhibitors in TRK fusion-positive cancers
Drilon, A. E. D. C. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz282 · Cited by 297 · see citing works
Hayashida, Y., Hirai, T., Morishita, S., Kitajima, M., Murakami, R., Korogi, Y., Makino, K., Nakamura, H., Ikushima, I., Yamura, M., et al. (2006) · PubMed Central · Cited by 296 · see citing works
Sandmann, T., Bourgon, R., Garcia, J., Li, C., Cloughesy, T. F., Chinot, O. L., Wick, W., Nishikawa, R., Mason, W. P., Henriksson, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.5005 · Cited by 293 · see citing works
Self-citationJohanns, T. M., Miller, C. A., Dorward, I. G., Tsien, C. I., Chang, E. F., Perry, A., Uppaluri, R., Ferguson, C., Schmidt, R. E., Dahiya, S. M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0575 · Cited by 290 · see citing works
Wen, P. Y., Reardon, D. A., Armstrong, T. S., Phuphanich, S., Aiken, R. D., Landolfi, J. C., Curry, W. T., Zhu, J., Glantz, M., Peereboom, D. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0261 · Cited by 290 · see citing works
Self-citation<i>EGFR</i> Variant Heterogeneity in Glioblastoma Resolved through Single-Nucleus Sequencing
Francis, J. M., Zhang, C.-Z., Maire, C. L., Jung, J., Manzo, V. E., Adalsteinsson, V. A., Homer, H., Haidar, S., Blumenstiel, B., Pedamallu, C. S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0879 · Cited by 287 · see citing works
NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma
Weiß, T., Weller, M., Gückenberger, M., Sentman, C. L., & Roth, P. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1788 · Cited by 286 · see citing works
Self-citationBrandes, A. A., Carpentier, A. F., Kesari, S., Sepulveda-Sanchez, J. M., Wheeler, H. R., Chinot, O., Cher, L., Steinbach, J. P., Capper, D., Specenier, P., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now009 · Cited by 273 · see citing works
Self-citationRapp, S. R., Case, L. D., Peiffer, A. M., Naughton, M. M., Chan, M. D., Stieber, V. W., Moore, D. F., Falchuk, S. C., Piephoff, J. V., Edenfield, W. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.4508 · Cited by 270 · see citing works
Ringel, F. A., Pape, H., Sabel, M., Krex, D., Bock, H. C., Misch, M., Weyerbrock, A., Westermaier, T., Senft, C., Schucht, P., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov145 · Cited by 266 · see citing works
Chiocca, E. A., Yu, J. S., Lukas, R. V., Solomon, I. H., Ligon, K. L., Nakashima, H., Triggs, D., Reardon, D. A., Wen, P. Y., Stopa, B. M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw5680 · Cited by 264 · see citing works
Self-citationKörber, V., Yang, J., Barah, P., Wu, Y., Stichel, D., Gu, Z., Fletcher, M. N. C., Jones, D., Hentschel, B., Lamszus, K., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.007 · Cited by 260 · see citing works
Self-citationSuchorska, B., Weller, M., Tabatabai, G., Senft, C., Hau, P., Sabel, M., Herrlinger, U., Ketter, R., Schlegel, U. S., Marosi, C., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov326 · Cited by 255 · see citing works
Self-citationPerry, J., Julian, J. A., Laperrière, N., Geerts, W. H., Agnelli, G., Rogers, L., Malkin, M. G., Sawaya, R. A., Baker, R. I., Falanga, A., et al. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03973.x · Cited by 249 · see citing works
Ellingson, B. M., Chung, C. D., Pope, W. B., Boxerman, J. L., & Kaufmann, T. J. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2375-2 · Cited by 247 · see citing works
Belcaid, Z., Phallen, J. A., Zeng, J., See, A. P., Mathios, D., Gottschalk, C., Nicholas, S. E., Kellett, M. D., Ruzevick, J., Jackson, C. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101764 · Cited by 243 · see citing works
Self-citationGlobal incidence of malignant brain and other central nervous system tumors by histology, 2003–2007
Leece, R., Xu, J. C., Ostrom, Q. T., Chen, Y., Kruchko, C. A., & Barnholtz‐Sloan, J. S. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox091 · Cited by 235 · see citing works
Self-citationApplication of Novel Response/Progression Measures for Surgically Delivered Therapies for Gliomas
Vogelbaum, M. A., Jost, S. C., Aghi, M. K., Heimberger, A. B., Sampson, J. H., Wen, P. Y., Macdonald, D., van den Bent, M. J., & Chang, S. M. (2011) · Neurosurgery · doi:10.1227/neu.0b013e318223f5a7 · Cited by 231 · see citing works
Self-citationAssociation Between Hyperglycemia and Survival in Patients With Newly Diagnosed Glioblastoma
Derr, R. L., Ye, X., Islas, M. U., Desideri, S., Saudek, C. D., & Grossman, S. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.1098 · Cited by 225 · see citing works
Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE
Alexander, B. M., Ba, S., Berger, M. S., Berry, D. A., Cavenee, W. K., Chang, S. M., Cloughesy, T. F., Jiang, T., Khasraw, M., Li, W., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0764 · Cited by 225 · see citing works
Self-citationGlantz, M., Cole, B. F., Friedberg, M. H., Lathi, E. S., Choy, H., Furie, K. L., Akerley, W., Wahlberg, L. U., Lekos, A., & Louis, S. (1996) · Neurology · doi:10.1212/wnl.46.4.985 · Cited by 220 · see citing works
Tesileanu, C. M. S., Dirven, L., Wijnenga, M. M. J., Koekkoek, J. A. F., Vincent, A. J. P. E., Dubbink, H. J., Atmodimedjo, P. N., Kros, J. M., van Duinen, S. G., Smits, M., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz200 · Cited by 216 · see citing works
Self-citationButler, J. M., Case, L. D., Atkins, J., Frizzell, B., Sanders, G., Griffin, P., Lesser, G., McMullen, K., McQuellon, R., Naughton, M., et al. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.05.076 · Cited by 214 · see citing works
Quillien, V., Lavenu, A., Karayan, L., Carpentier, C., Labussière, M., Lesimple, T., Chinot, O. L., Wager, M., Honnorat, J., Saïkali, S., et al. (2012) · Cancer · doi:10.1002/cncr.27392 · Cited by 213 · see citing works
Self-citationKreth, F.-W., Thon, N., Simon, M., Westphal, M., Schackert, G., Nikkhah, G., Hentschel, B., Reifenberger, G., Pietsch, T., Weller, M., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt388 · Cited by 211 · see citing works
Self-citationChi, A. S., Tarapore, R. S., Hall, M. D., Shonka, N., Gardner, S. L., Umemura, Y., Sumrall, A. L., Khatib, Z. A., Mueller, S., Kline, C., et al. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03271-3 · Cited by 199 · see citing works
Self-citationvan den Bent, M. J., Eoli, M., Sepúlveda-Sánchez, J. M., Smits, M., Walenkamp, A., Frenel, J., Franceschi, E., Clement, P., Chinot, O. L., Vos, F. D., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz222 · Cited by 199 · see citing works
Self-citationPhase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma
Cloughesy, T. F., Landolfi, J. C., Hogan, D. J., Bloomfield, S. M., Carter, B. S., Chen, C. C., Elder, J. B., Kalkanis, S. N., Kesari, S., Lai, A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9784 · Cited by 195 · see citing works
Self-citationPhase I Study of GRN1005 in Recurrent Malignant Glioma
Drappatz, J., Brenner, A., Wong, E. T., Eichler, A., Schiff, D., Groves, M. D., Mikkelsen, T., Rosenfeld, S., Sarantopoulos, J., Meyers, C. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2481 · Cited by 190 · see citing works
Self-citationA metabolic function of FGFR3-TACC3 gene fusions in cancer
Frattini, V., Pagnotta, S. M., Tala, Fan, J. J., Russo, M. V., Lee, S. B., Garofano, L., Zhang, J., Shi, P., Lewis, G., et al. (2018) · Nature · doi:10.1038/nature25171 · Cited by 189 · see citing works
Self-citationEllsworth, S. G. (2018) · Advances in Radiation Oncology · doi:10.1016/j.adro.2018.08.014 · Cited by 189 · see citing works
Addressing Diffuse Glioma as a Systemic Brain Disease With Single-Cell Analysis
Capper, D. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.2910 · Cited by 187 · see citing works
Chang, K., Beers, A. L., Bai, H. X., Brown, J. M., Ly, I., Li, X., Senders, J. T., Kavouridis, V. K., Boaro, A., Su, C., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz106 · Cited by 182 · see citing works
Self-citationGulati, S., Jakola, A. S., Nerland, U. S., Weber, C., & Solheim, O. S. (2011) · World Neurosurgery · doi:10.1016/j.wneu.2011.06.014 · Cited by 181 · see citing works
Prophylactic Anticonvulsants in Patients with Brain Tumour
Forsyth, P. A., Weaver, S., Fulton, D. S., Brasher, P. M. A., Sutherland, G. R., Stewart, D., Hagen, N. A., Barnes, P. J., Cairncross, J. G., & DeAngelis, L. M. (2003) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100053361 · Cited by 180 · see citing works
Carruthers, R., Ahmed, S. U., Ramachandran, S., Strathdee, K. E., Kurian, K. M., Hedley, A., Gomez-Roman, N., Kalna, G., Neilson, M., Gilmour, L., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0569 · Cited by 180 · see citing works
The DNA Damaging Revolution: PARP Inhibitors and Beyond
Yap, T. A., Plummer, R., Azad, N. S., & Helleday, T. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238473 · Cited by 175 · see citing works
Mutant IDH1 and thrombosis in gliomas
Unruh, D. J., Schwarze, S. R., Khoury, L., Thomas, C., Wu, M., Chen, L., Chen, R., Liu, Y., Schwartz, M. A., Amidei, C., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1620-7 · Cited by 173 · see citing works
Self-citationWen, P. Y., Chang, S., Lamborn, K. R., Kuhn, J. G., Norden, A. D., Cloughesy, T. F., Robins, H. I., Lieberman, F. S., Gilbert, M. R., Mehta, M. P., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not247 · Cited by 171 · see citing works
Self-citation
Flagged first, then by citations
4 of the 334 references couldn’t be matched to a known paper.
Research works printed but not linked: 5
- Davis FG, Smith T, Gittleman H, Ostrom Q, Kruchko C, Barnholtz-Sloan JS. Glioblastoma multiforme incidence in Canada and the US in comparison with England 1995-2015. Neuro Oncol. 2019; In Press.
- Tomita-Mitchell A, Kat AG, Marcelino LA, Li-Sucholeiki XC, Goodluck-Griffith J, Thilly WG. Mismatch repair deficient human cells: spontaneous and MNNG-induced mutational spectra in the HPRT gene. Mutat Res. 2000; 450(1-2):125-138.
- Quillien V, Lavenu A, Karayan-Tapon L, et al. Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze · DOI
- A c c e p t e d M a n u s c r i p t 56 O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer. 2012; 118(17):4201-4211.
- SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015; 16(13):1324-1334. 305.
Cited by
Sorted by citations
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Weller, M., van den Bent, M., Preusser, M., Le Rhun, E., Tonn, J. C., Minniti, G., Bendszus, M., Balana, C., Chinot, O., Dirven, L., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00447-z · Cited by 2,048 · see citing works
Self-citationGlioblastoma and Other Primary Brain Malignancies in Adults
Schaff, L. R., & Mellinghoff, I. K. (2023) · JAMA · doi:10.1001/jama.2023.0023 · Cited by 1,334 · see citing works
Self-citationNetwork pharmacology: curing causal mechanisms instead of treating symptoms
Nogales, C., Mamdouh, Z. M., List, M., Kiel, C., Casas, A. I., & Schmidt, H. H. H. W. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.11.004 · Cited by 1,232 · see citing works
Weller, M., Wen, P. Y., Chang, S. M., Dirven, L., Lim, M. K., Monje, M., & Reifenberger, G. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00516-y · Cited by 645 · see citing works
Self-citationHara, T., Chanoch-Myers, R., Mathewson, N. D., Myskiw, C., Atta, L., Bussema, L., Eichhorn, S. W., Greenwald, A., Kinker, G. S., Rodman, C., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.05.002 · Cited by 593 · see citing works
“Despite extensive efforts to translate the basic glioblastoma biology to patients, molecularly targeted therapies have largely failed in trials over the past decade (Gilbert et al., 2014; Wen et al., 2020).”
Lim, M. K., Weller, M., Idbaïh, A., Steinbach, J. P., Finocchiaro, G., Raval, R. R., Ansstas, G., Baehring, J. M., Taylor, J. W., Honnorat, J., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac116 · Cited by 551 · see citing works
Self-citationCentral Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Nabors, B., Portnow, J., Ahluwalia, M. S., Baehring, J. M., Brem, H., Brem, S. S., Butowski, N. A., Campian, J. L., Clark, S. W., Fabiano, A. J., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0052 · Cited by 543 · see citing works
Self-citationOmuro, A. M. P., Brandes, A. A., Carpentier, A. F., Idbaïh, A., Reardon, D. A., Cloughesy, T. F., Sumrall, A. L., Baehring, J. M., van den Bent, M. J., Bähr, O., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac099 · Cited by 533 · see citing works
“Given the lack of treatment alternatives, TMZ is offered to all patients with glioblastoma, regardless of tumor MGMT promoter methylation status—with or without tumor-treating fields.(4,6,12) Because of TMZ’s minimal benefit and known toxicities, reassessment of its role in glioblastoma with unmethylated MGMT promoter…”
BackgroundSelf-citationWen, P. Y., van den Bent, M. J., Youssef, G., Cloughesy, T. F., Ellingson, B. M., Weller, M., Galanis, E., Barboriak, D. P., de Groot, J., Gilbert, M. R., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01059 · Cited by 519 · see citing works
Self-citationGlioma progression is shaped by genetic evolution and microenvironment interactions
Varn, F. S., Johnson, K. C., Martinek, J., Huse, J. T., Nasrallah, M. P., Wesseling, P., Cooper, L., Malta, T. M., Wade, T. E., Sabedot, T. S., et al. (2022) · Cell · doi:10.1016/j.cell.2022.04.038 · Cited by 495 · see citing works
Self-citationSingle-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target
Abdelfattah, N., Kumar, P., Wang, C., Leu, J.-S., Flynn, W. F., Gao, R., Baskin, D. S., Pichumani, K., Ijare, O. B., Wood, S. L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28372-y · Cited by 469 · see citing works
Karschnia, P., Young, J. S., Dono, A., Häni, L., Sciortino, T., Bruno, F., Juenger, S. T., Teske, N., Morshed, R. A., Haddad, A. F., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac193 · Cited by 418 · see citing works
“We aimed to (1) explore the prognostic utility of the classification system and (2) define how much removed non-CE tumor translates into a survival benefit.”
BackgroundMethodSelf-citationGlioblastoma: clinical presentation, diagnosis, and management
McKinnon, C., Nandhabalan, M., Murray, S. A., & Plaha, P. (2021) · BMJ · doi:10.1136/bmj.n1560 · Cited by 401 · see citing works
Bagley, S. J., Logun, M. T., Fraietta, J. A., Wang, X., Desai, A. S., Bagley, L. J., Nabavizadeh, A., Jarocha, D. J., Martins, R., Maloney, E., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02893-z · Cited by 395 · see citing works
“Moreover, patient 1 experienced acute onset headache, nausea and vomiting that may have indicated elevated intracranial pressure, and patients 1, 2, 5 and 6 experienced acute worsening of chronic neurological deficits attributable to tumor location(s): all signs and symptoms potentially consistent…”
BackgroundWen, P. Y., Stein, A., van den Bent, M. J., Greve, J. D., Wick, A., Vos, F. D., von Bubnoff, N., van Linde, M. E., Lai, A., Prager, G. W., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00578-7 · Cited by 377 · see citing works
Self-citationBrown, C. E., Hibbard, J. C., Alizadeh, D., Blanchard, M. S., Natri, H. M., Wang, D., Ostberg, J. R., Aguilar, B., Wagner, J. R., Paul, J. A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02875-1 · Cited by 372 · see citing works
Immunotherapy for glioblastoma: current state, challenges, and future perspectives
Liu, Y., Fei, Z., Ali, H. A., Lathia, J. D., & Chen, P. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01226-x · Cited by 367 · see citing works
“GBM is the most aggressive and malignant form of glioma, with an mOS of only 12 – 18 months [3].”
Berger, T. R., Wen, P. Y., Lang‐Orsini, M., & Chukwueke, U. N. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.2844 · Cited by 320 · see citing works
Self-citationGlioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol‐Caballo, M., López‐Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Bonet, L. G. G., Martínez‐Cadenas, C., Estrela, J. M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 263 · see citing works
Mellinghoff, I. K., Lu, M., Wen, P. Y., Taylor, J. W., Maher, E. A., Arrillaga‐Romany, I., Peters, K. B., Ellingson, B. M., Rosenblum, M. K., Chun, S., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02141-2 · Cited by 251 · see citing works
Self-citationMacrophages and microglia: the cerberus of glioblastoma
Buonfiglioli, A., & Hambardzumyan, D. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01156-z · Cited by 236 · see citing works
“These tumors are chemo- and radiotherapy resistant [216].”
BackgroundRecurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives
Birzu, C., French, P. J., Caccese, M., Cerretti, G., Idbaïh, A., Zagonel, V., & Lombardi, G. (2020) · Cancers · doi:10.3390/cancers13010047 · Cited by 218 · see citing works
“To date, a limited number of clinical trials have investigated this field, mostly in newly diagnosed GBM, but the final results were deceiving, thus highlighting the need for further exploration [5].”
BackgroundResultInfluentialEvidence-based recommendations on categories for extent of resection in diffuse glioma
Karschnia, P., Vogelbaum, M. A., van den Bent, M. J., Cahill, D. P., Bello, L., Narita, Y., Berger, M. S., Weller, M., & Tonn, J. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.002 · Cited by 209 · see citing works
Self-citationBagley, S. J., Binder, Z. A., Lamrani, L., Marinari, E., Desai, A. S., Nasrallah, M. P., Maloney, E., Brem, S. S., Lustig, R. A., Kurtz, G. A., et al. (2024) · Nature Cancer · doi:10.1038/s43018-023-00709-6 · Cited by 199 · see citing works
“One patient had a severe immune-related radiation and temozolomide 7 , median overall survival (OS) remains 15–18 months 8 .”
BackgroundGlioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement
Bagley, S. J., Kothari, S., Rahman, R. M., Lee, E. Q., Dunn, G. P., Galanis, E., Chang, S. M., Nabors, B., Ahluwalia, M. S., Stupp, R., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2750 · Cited by 167 · see citing works
“However, variations of this regimen are used in clinical practice and supported by National Comprehensive Cancer Network (NCCN) and other guidelines (1), including hypofractionated radiation (e.”
BackgroundMethodSelf-citationA Review of Newly Diagnosed Glioblastoma
Oronsky, B. T., Reid, T. R., Oronsky, A. L., Sandhu, N., & Knox, S. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.574012 · Cited by 167 · see citing works
Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma
Naghavian, R., Faigle, W., Oldrati, P., Wang, J., Toussaint, N. C., Qiu, Y., Medici, G., Wacker, M., Freudenmann, L. K., Bonté, P.-E., et al. (2023) · Nature · doi:10.1038/s41586-023-06081-w · Cited by 163 · see citing works
Self-citationAlbert, N., Galldiks, N., Ellingson, B., van den Bent, M. J., Chang, S. M., Cicone, F., de Groot, J. D., Koh, E., Law, I., Rhun, É. L., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00525-9 · Cited by 126 · see citing works
Self-citationLactate dehydrogenase A regulates tumor-macrophage symbiosis to promote glioblastoma progression
Khan, F., Lin, Y., Ali, H. A., Pang, L., Dunterman, M., Hsu, W.-H., Frenis, K., Rowe, R. G., Wainwright, D. A., McCortney, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46193-z · Cited by 158 · see citing works
Self-citationPD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?
Khasraw, M., Reardon, D. A., Weller, M., & Sampson, J. H. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1135 · Cited by 128 · see citing works
“an overall survival or progression-free survival advantage (3)”
BackgroundInfluentialSelf-citationGalldiks, N., Niyazi, M., Grosu, A., Köcher, M., Langen, K., Law, I. G., Minniti, G. C., Kim, M. M., Tsien, C. I., Dhermain, F. G., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab013 · Cited by 127 · see citing works
Self-citationGlioblastoma: An Update in Pathology, Molecular Mechanisms and Biomarkers
Lan, Z., Li, X., & Zhang, X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25053040 · Cited by 127 · see citing works
“It is highly aggressive and fast-growing and often diffusely invades the surrounding brain tissues, which makes it the deadliest form of tumor in the brain [5,6].”
BackgroundInfluentialSun, S., Gao, T., Pang, B., Su, X., Guo, C., Zhang, R., & Pang, Q. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04524-2 · Cited by 124 · see citing works
Disconnecting multicellular networks in brain tumours
Venkataramani, V., Schneider, M. B., Giordano, F. A., Kuner, T., Wick, W., Herrlinger, U., & Winkler, F. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00475-0 · Cited by 122 · see citing works
“This can be approached in two ways: (1) MRI can be performed in the context of autopsies105,107–109, giving the opportunity to correlate MRI and histological parameters on a single-cell level with high-resolution microscopy parameters, and (2) in the context of a standardized supramarginal resection (for example, ante…”
BackgroundSelf-citationLogun, M. T., Wang, X., Sun, Y. Y., Bagley, S. J., Li, N., Desai, A. S., Zhang, D. Y., Nasrallah, M. P., Pai, E. L.-L., Oner, B. S., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.11.010 · Cited by 119 · see citing works
Targeting Glioblastoma Stem Cells: A Review on Biomarkers, Signal Pathways and Targeted Therapy
Tang, X., Zuo, C., Fang, P., Liu, G., Qiu, Y., Huang, Y., & Tang, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.701291 · Cited by 122 · see citing works
Chiocca, E. A., Gelb, A. B., Chen, C. C., Rao, G., Reardon, D. A., Wen, P. Y., Bi, W. L., Peruzzi, P., Amidei, C., Triggs, D., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab271 · Cited by 115 · see citing works
Self-citationTargeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug
Bi, J., Khan, A. A., Tang, J., Armando, A. M., Wu, S., Zhang, W., Gimple, R. C., Reed, A., Jing, H., Koga, T., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109957 · Cited by 113 · see citing works
“…landscape of GBM, genomic insights have failed to translate into improved survival for the vast majority of patients, most of whom still die within 2 years, despite aggressive treatment with surgical resection, radiotherapy, and temozolomide (TMZ) (Cloughesy et al., 2014; Wen et al., 2020).”
Self-citationTowards controlled drug delivery in brain tumors with microbubble-enhanced focused ultrasound
Schoen, S. J., Kilinc, M. S., Lee, H., Guo, Y., Degertekin, F. L., Woodworth, G. F., & Arvanitis, C. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114043 · Cited by 113 · see citing works
Sahm, F., Brandner, S., Bertero, L., Capper, D., French, P. J., Figarella-Branger, D. F., Giangaspero, F., Haberler, C., Hegi, M. E., Kristensen, B. W., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad100 · Cited by 113 · see citing works
“93 As a next step, the relevance of treatment related diagnostics should be proven and care providers should reimburse also deducted therapies.”
BackgroundSelf-citationArtificial intelligence-based MRI radiomics and radiogenomics in glioma
Fan, H., Luo, Y., Gu, F., Tian, B., Xiong, Y., Wu, G., Nie, X., Yu, J., Tong, J., & Liao, X. (2024) · Cancer Imaging · doi:10.1186/s40644-024-00682-y · Cited by 108 · see citing works
“In the past decade, critical advances in understanding the molecular biology underlying GBM have been obtained, but few has been translated into improved diagnosis and prognosis for patients [7].”
BackgroundExtracellular matrix in glioblastoma: opportunities for emerging therapeutic approaches.
Mohiuddin, E., & Wakimoto, H. (2021) · PubMed Central · Cited by 105 · see citing works
Karschnia, P., Dono, A., Young, J. S., Juenger, S. T., Teske, N., Häni, L., Sciortino, T., Mau, C. Y., Bruno, F., Núñez, L., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad074 · Cited by 107 · see citing works
“Patients were selected based on the following criteria: (1) first radiographic recurrence of a previously resected IDH wild-type glioblastoma per WHO 2021 classification,10 (2) information on treatment and outcome following first recurrence available for review, and (3) pre-and post-operative magnetic resonance imagin…”
MethodSelf-citationSim, H., McDonald, K. L., Lwin, Z., Barnes, E. H., Rosenthal, M. A., Foote, M. C., Koh, E., Back, M., Wheeler, H., Sulman, E. P., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab111 · Cited by 102 · see citing works
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
Lassman, A. B., Sepúlveda-Sánchez, J. M., Cloughesy, T. F., Gil-Gil, M. J., Puduvalli, V. K., Raizer, J. J., Vos, F. D., Wen, P. Y., Butowski, N. A., Clément, P. M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2664 · Cited by 102 · see citing works
“Glioblastomas, the most common type of primary brain tumor, are particularly aggressive with a median overall survival (OS) of 15 to 18 months after standard care (3).”
BackgroundSelf-citationGlioblastoma Organoids: Pre-Clinical Applications and Challenges in the Context of Immunotherapy
Klein, E., Hau, A., Oudin, A., Golebiewska, A., & Niclou, S. P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.604121 · Cited by 98 · see citing works
Coy, S., Wang, S., Stopka, S. A., Lin, J., Yapp, C., Ritch, C. C., Salhi, L., Baker, G. J., Rashid, R., Baquer, G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32430-w · Cited by 98 · see citing works
Self-citationDewdney, B., Jenkins, M. R., Best, S. A., Freytag, S., Prasad, K., Holst, J., Endersby, R., & Johns, T. G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01637-8 · Cited by 100 · see citing works
Karschnia, P., Gerritsen, J. K. W., Teske, N., Cahill, D. P., Jakola, A. S., van den Bent, M. J., Weller, M., Schnell, O., Vik-Mo, E. O., Thon, N., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00130-x · Cited by 116 · see citing works
Self-citationTargeting immunoliposomes to EGFR-positive glioblastoma
Kasenda, B., König, D., Manni, M., Ritschard, R., Duthaler, U., Bartoszek, E., Bärenwaldt, A., Deuster, S., Hütter, G., Cordier, D., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2021.100365 · Cited by 95 · see citing works
Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme
Aldoghachi, A. F., Aldoghachi, A. F., Breyne, K., Ling, K., & Cheah, P.-S. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.03.030 · Cited by 94 · see citing works
Updates in IDH-Wildtype Glioblastoma
Melhem, J. M., Detsky, J. S., Lim-Fat, M. J., & Perry, J. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01251-6 · Cited by 89 · see citing works
Leveraging external data in the design and analysis of clinical trials in neuro-oncology
Rahman, R. M., Ventz, S., McDunn, J., Louv, B., Reyes‐Rivera, I., Polley, M. C., Merchant, F., Abrey, L. E., Allen, J. E., Aguilar, L. K., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00488-5 · Cited by 86 · see citing works
Self-citationWen, P. Y., Weller, M., Lee, E. Q., Touat, M., Khasraw, M., Rahman, R. M., Platten, M., Lim, M. K., Winkler, F., Horbinski, C., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf177 · Cited by 95 · see citing works
Self-citationHertler, C., Felsberg, J., Gramatzki, D., Rhun, É. L., Clarke, J. L., Soffietti, R., Wick, W., Chinot, O. L., Ducray, F., Roth, P., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.05.002 · Cited by 85 · see citing works
“Factors usually associated with longer survival include young age, good Karnofsky performance status (KPS) at diagnosis, and O 6 -methylguanine DNA methyltransferase ( MGMT) promoter methylation [1,2,7,8].”
Self-citationTawil, N., Bassawon, R., Meehan, B., Nehme, A., Montermini, L., Gayden, T., Jay, N. D., Spinelli, C., Chennakrishnaiah, S., Choi, D., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020002998 · Cited by 82 · see citing works
Self-citationDistinct metabolic hallmarks of WHO classified adult glioma subtypes
Björkblom, B., Wibom, C., Eriksson, M., Bergenheim, A. T., Sjöberg, R. L., Jonsson, P., Brännström, T., Antti, H., Sandström, M., & Melin, B. S. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac042 · Cited by 78 · see citing works
“26 This finding indicates that the 45-year-old glioblastoma age group might carry less aggressive tumors more similar to lower grade astrocytoma, which is in line with our metabolomic characterization.”
Neurological complications of cancer immunotherapy
Roth, P., Winklhofer, S. F.-X., Müller, A. M. S., Dummer, R., Mair, M. J., Gramatzki, D., Rhun, É. L., Manz, M. G., Weller, M., & Preusser, M. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102189 · Cited by 78 · see citing works
“While continued awareness is mandatory, there are so far no specific concerns regarding the safety and neurological tolerability of ICI in patients with brain tumors, which allows further clinical investigation in these patients [58].”
BackgroundSelf-citationSun, S., Guo, C., Gao, T., Ma, D., Su, X., Pang, Q., & Zhang, R. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/7862430 · Cited by 78 · see citing works
“[38].”
Circadian regulator CLOCK promotes tumor angiogenesis in glioblastoma
Pang, L., Dunterman, M., Xuan, W., Gonzalez, A. M., Lin, Y., Hsu, W.-H., Khan, F., Hagan, R. S., Müller, W. A., Heimberger, A. B., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112127 · Cited by 78 · see citing works
Extracellular Vesicle-Mediated Bilateral Communication between Glioblastoma and Astrocytes
Nieland, L., Morsett, L. M., Broekman, M. L. D., Breakefield, X. O., & Abels, E. R. (2020) · Trends in Neurosciences · doi:10.1016/j.tins.2020.10.014 · Cited by 77 · see citing works
“The heterogeneity of glioblastoma occurs at multiple levels which makes this brain tumor challenging to study and currently incurable [4].”
BackgroundNunno, V. D., Gatto, L., Tosoni, A., Bartolini, S., & Franceschi, E. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1067252 · Cited by 77 · see citing works
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
Lassman, A. B., Sepúlveda-Sánchez, J. M., Cloughesy, T. F., Gil‐Gil, M., Puduvalli, V. K., Raizer, J. J., Vos, F. D., Wen, P. Y., Butowski, N. A., Clément, P. M., et al. (2022) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-230044 · Cited by 76 · see citing works
Self-citationZhu, H., Allwin, C., Bassous, M. G., & Pouliopoulos, A. N. (2024) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04795-z · Cited by 75 · see citing works
“Brain tumors continue to exhibit a poor prognosis, with less than 20% of patients surviving beyond 5 years post-diagnosis [1].”
BackgroundNew hints towards a precision medicine strategy for IDH wild-type glioblastoma
White, K., Connor, K., Clerkin, J., Murphy, B. M., Salvucci, M., O’Farrell, A. C., Rehm, M., O’Brien, D., Prehn, J. H. M., Niclou, S. P., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2336 · Cited by 75 · see citing works
“A comprehensive review focused on the current management of IDH-wt GBM with consideration also given to future directions has recently been published.(49)”
Self-citationComba, A., Faisal, S. M., Varela, M. L., Hollon, T. C., Al‐Holou, W. N., Umemura, Y., Núñez, F. J., Motsch, S., Castro, M. G., & Lowenstein, P. R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703764 · Cited by 76 · see citing works
Roder, C., Stummer, W., Coburger, J., Scherer, M., Haas, P., von der Brelie, C., Kamp, M. A., Löhr, M., Hamisch, C., Skardelly, M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01862 · Cited by 73 · see citing works
Harwood, D. S. L., Pedersen, V., Bager, N. S., Schmidt, A. Y., Stannius, T. O., Areškevičiūtė, A., Josefsen, K. E., Nørøxe, D. S., Scheie, D., Rostalski, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52167-y · Cited by 73 · see citing works
Assessment and prediction of glioblastoma therapy response: challenges and opportunities
Qi, D., Li, J., Quarles, C. C., Fonkem, E., & Wu, E. (2022) · Brain · doi:10.1093/brain/awac450 · Cited by 72 · see citing works
Hou, A. J., Shih, R. M., Uy, B. R., Shafer, A. M., Chang, Z. L., Comin-Anduix, B., Güemes, M., Galić, Z., Phyu, S. M., Okada, H., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae126 · Cited by 77 · see citing works
Self-citationExtracellular vesicles and oncogenic signaling
Schubert, A., & Boutros, M. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12855 · Cited by 69 · see citing works
A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma
Lassman, A. B., Wen, P. Y., van den Bent, M. J., Plotkin, S. R., Walenkamp, A., Green, A. L., Li, K., Walker, C. J., Chang, H., Tamir, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2225 · Cited by 70 · see citing works
“Glioblastoma (GBM) is the most common primary brain tumor in adults (1), with a poor prognosis (2).”
BackgroundSelf-citationNanoscale Drug Delivery Systems in Glioblastoma
Liu, Z., Ji, X., Dong, H., Zhang, R., Liu, Q., & Xin, T. (2022) · Nanoscale Research Letters · doi:10.1186/s11671-022-03668-6 · Cited by 70 · see citing works
“The standard therapy for GBM is maximal safe resection followed by adjuvant radiation and oral temolozomide (TMZ), which extends patients’ life expectancy only by 16 to 18 months [1].”
MethodOmuro, A. M. P., Reardon, D. A., Sampson, J. H., Baehring, J. M., Sahebjam, S., Cloughesy, T. F., Chalamandaris, A.-G., Potter, V., Butowski, N. A., & Lim, M. K. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac025 · Cited by 69 · see citing works
Self-citationFunctional Contribution and Clinical Implication of Cancer-Associated Fibroblasts in Glioblastoma
Galbo, P. M., Madsen, A. T., Liu, Y., Peng, M., Yao, W., Ciesielski, M. J., Fenstermaker, R. A., Graff, S., Montagna, C., Segall, J. E., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0493 · Cited by 69 · see citing works
Principles in the Management of Glioblastoma
Roda, D., Veiga, P., Melo, J. B., Carreira, I. M., & Ribeiro, I. P. (2024) · Genes · doi:10.3390/genes15040501 · Cited by 69 · see citing works
EMP3 mediates glioblastoma‐associated macrophage infiltration to drive T cell exclusion
Chen, Q., Jin, J., Huang, X., Wu, F., Huang, H., & Zhan, R. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01954-2 · Cited by 68 · see citing works
“While immunotherapy-based approaches have been widely attempted, most clinical trials involving these modalities have failed to report significant outcomes [26, 27].”
BackgroundSenthilathiban, D. P., Biswas, I., Kuduvalli, S. S., & Anitha, T. S. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110350 · Cited by 68 · see citing works
Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma
Pang, L., Khan, F., Heimberger, A. B., & Chen, P. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2022.04.010 · Cited by 67 · see citing works
“The current standard of care for patients with GBM includes maximal surgical resection followed by radiotherapy and/or chemotherapy, which offers minimal clinical bene fi ts [1,2].”
BackgroundMethodPathogenetic Features and Current Management of Glioblastoma
Nguyen, H.-M., Guz-Montgomery, K., Lowe, D. B., & Saha, D. (2021) · Cancers · doi:10.3390/cancers13040856 · Cited by 67 · see citing works
“cell cycle arrest and apoptosis [156] and include drugs such as palbociclib, ribociclib or abemaciclib that are FDA approved for other cancer types and are currently being clinically evaluated in GBM (Table 2) [157,158].”
BackgroundFurtner, J., Weller, M., Weber, M., Gorlia, T., Nabors, B., Reardon, D. A., Tonn, J. C., Stupp, R., & Preusser, M. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1987 · Cited by 67 · see citing works
“Despite a multimodal treatment scheme comprised of neurosurgical intervention and concurrent chemoradiotherapy with temozolomide, recurrence within 1 year occurs in most patients (2, 3).”
BackgroundSelf-citationLiu, D., Cheng, Y., Qiao, S., Liu, M., Ji, Q., Zhang, B., Mei, Q., & Zhou, S. (2022) · ACS Nano · doi:10.1021/acsnano.1c09794 · Cited by 66 · see citing works
Zhao, J., Yang, S., Cui, X., Wang, Q., Yang, E., Tong, F., Hong, B., Xiao, M., Lei, X., Xu, C., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac242 · Cited by 66 · see citing works
Spatial architecture of high-grade glioma reveals tumor heterogeneity within distinct domains
Moffet, J. J. D., Fatunla, E. O., Freytag, L., Kriel, J., Jones, J., Roberts-Thomson, S. J., Pavenko, A., Scoville, D., Zhang, L. N., Liang, Y., et al. (2023) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdad142 · Cited by 66 · see citing works
“8,9 Thus, patients still receive radiation and alkylating chemotherapy 4,5,10,11 using regimens unchallenged for the past 25 years, highlighting a need for improved stratification and treatment options.”
Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma
Duraj, T., Kalamian, M., Zuccoli, G., Maroon, J. C., D’Agostino, D. P., Scheck, A. C., Poff, A. M., Winter, S. F., Hu, J. L., Klement, R. J., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03775-4 · Cited by 64 · see citing works
Youssef, G., Rahman, R. M., Bay, C. P., Wang, W., Lim-Fat, M. J., Arnaout, O. M., Bi, W. L., Cagney, D. N., Chang, Y.-S., Cloughesy, T. F., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01579 · Cited by 64 · see citing works
“Time interval between end of radiation and postradiation MRI, days, median (range) 28 (3-47)”
BackgroundInfluentialSelf-citationde Groot, J., Kim, A. H., Prabhu, S. S., Rao, G., Laxton, A. W., Fecci, P. E., O'Brien, B. J., Sloan, A. E., Chiang, V., Tatter, S. B., et al. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac040 · Cited by 63 · see citing works
Giordano, F. A., Layer, J. P., Leonardelli, S., Friker, L. L., Turiello, R., Corvino, D., Zeyen, T., Schaub, C., Müller, W. C., Sperk, E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48416-9 · Cited by 63 · see citing works
“Thepatient characteristics areprovidedinSupplementaryTable 3.”
Self-citationZeng, A., Wei, Z., Rabinovsky, R., Jun, H. J., Fatimy, R. E., Deforzh, E., Arora, R., Yao, Y., Yao, S., Yan, W., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101420 · Cited by 62 · see citing works
The Role of Hypoxia and SRC Tyrosine Kinase in Glioblastoma Invasiveness and Radioresistance
Torrisi, F., Vicario, N., Spitale, F. M., Cammarata, F. P., Minafra, L., Salvatorelli, L., Russo, G. I., Cuttone, G., Valable, S., Gulino, R., et al. (2020) · Cancers · doi:10.3390/cancers12102860 · Cited by 59 · see citing works
“, temozolomide), and radiotherapy [1].”
Function of exosomes in neurological disorders and brain tumors
Xiao, L., Hareendran, S., & Loh, Y. P. (2021) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2021.04 · Cited by 62 · see citing works
Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives
Sener, U. T., Ruff, M. W., & Campian, J. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137046 · Cited by 61 · see citing works
“According to Central Brain Tumor Registry of the United States (CBTRUS), incidence is 3.23 per one hundred thousand with an average of 12,011 cases diagnosed per year between 2013 and 2017 [2].”
BackgroundInfluentialRahman, R. M., Trippa, L., Lee, E. Q., Arrillaga‐Romany, I., Fell, G. G., Touat, M., McCluskey, C. S., Wiley, J., Gaffey, S. C., Drappatz, J., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00493 · Cited by 61 · see citing works
Self-citationIn vitro biomimetic models for glioblastoma-a promising tool for drug response studies
Stanković, T., Ranđelović, T., Dragoj, M., Burić, S. S., Fernández, L. J., Ochoa, I., Pérez‐García, V. M., & Pešić, M. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100753 · Cited by 59 · see citing works
Advanced Imaging Techniques for Radiotherapy Planning of Gliomas
Castellano, A., Bailo, M., Cicone, F., Carideo, L., Quartuccio, N., Mortini, P., Falini, A., Cascini, G. L., & Minniti, G. C. (2021) · Cancers · doi:10.3390/cancers13051063 · Cited by 59 · see citing works
“8 Gy per fraction is the standard of care for adult grade 2 and 3 gliomas, followed by procarbazine, lomustine, vincristine (PCV chemotherapy), or temozolomide chemotherapy [2].”
BackgroundSelf-citationHypoxia-driven protease legumain promotes immunosuppression in glioblastoma
Pang, L., Guo, S., Khan, F., Dunterman, M., Ali, H. A., Liu, Y., Huang, Y.-Y., & Chen, P. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101238 · Cited by 58 · see citing works
Heuer, S., Burghaus, I., Gose, M., Keßler, T., Sahm, F., Vollmuth, P., Venkataramani, V., Hoffmann, D. C., Schlesner, M., Ratliff, M., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-11846-1 · Cited by 58 · see citing works
Self-citationGCN2 kinase activation by ATP-competitive kinase inhibitors
Tang, C. P., Clark, O., Ferrarone, J. R., Campos, C., Lalani, A. S., Chodera, J. D., Intlekofer, A. M., Elemento, O., & Mellinghoff, I. K. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00947-8 · Cited by 55 · see citing works
Self-citationCranioencephalic functional lymphoid units in glioblastoma
Dobersalske, C., Rauschenbach, L., Hua, Y., Berliner, C., Steinbach, A., Grüneboom, A., Kokkaliaris, K. D., Heiland, D. H., Berger, P., Langer, S., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03152-x · Cited by 56 · see citing works
“As our understanding of immunosurveillance in the brain continues to evolve, we can learn much from its disruption during malignant disease, for example, from glioblastoma, the most malignant adult brain cancer, that remains uniformly lethal with a median survival of less than 2 years 8 .”
InfluentialSelf-citationLiljedahl, E., Konradsson, E., Gustafsson, E., Förnvik, K., Olofsson, J. K., Ceberg, C. P., & Redebrandt, H. N. (2022) · Scientific Reports · doi:10.1038/s41598-022-16612-6 · Cited by 54 · see citing works
- Authors
- Wen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., Cloughesy, T. F., DeGroot, J. F., Galanis, E., Gilbert, M. R., Hegi, M. E., Horbinski, C., Huang, R. Y., Lassman, A. B., Le Rhun, E., Lim, M., Mehta, M. P., Mellinghoff, I. K., Minniti, G., Nathanson, D., Platten, M., Preusser, M., Roth, P., Sanson, M., Schiff, D., Short, S. C., Taphoorn, M. J. B., Tonn, J.-C., Tsang, J., Verhaak, R. G. W., von Deimling, A., Wick, W., Zadeh, G., Reardon, D. A., Aldape, K. D., & van den Bent, M. J.
- Affiliations
- Brigham and Women's Hospital (US)
- University of Zurich (CH)
- Case Western Reserve University School of Medicine and University Hospitals of Cleveland, Cleveland, Ohio, USA
- The Jackson Laboratory for Genomic Medicine (US)
- Yale University (US)
- University of California, San Francisco (US)
- University of California, Los Angeles (US)
- The University of Texas MD Anderson Cancer Center (US)
- Mayo Clinic (US)
- National Institutes of Health (US)
- Centre Hospitalier Universitaire Vaudois (CH)
- Northwestern University (US)
- NewYork–Presbyterian Hospital (US)
- University of Lille, Inserm, Neuro-oncology, General and Stereotaxic Neurosurgery service, University Hospital of Lille, Lille, France; Breast Cancer Department, Oscar Lambret Center, Lille, France and Department of Neurology & Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland
- Johns Hopkins University (US)
- Miami Cancer Institute, Miami, Florida, USA
- Memorial Sloan Kettering Cancer Center (US)
- University of Siena (IT)
- Heidelberg University (DE)
- Medical University of Vienna (AT)
- Centre National de la Recherche Scientifique (FR)
- University of Virginia (US)
- University of Leeds (GB)
- Leiden University Medical Center (NL)
- LMU Klinikum (DE)
- Neuropathology and Clinical Cooperation Unit Neuropathology, University Heidelberg and German Cancer Center, Heidelberg, Germany
- Princess Margaret Cancer Centre (CA)
- National Cancer Institute (US)
- Department of Neurology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
- Corresponding author
- Wen, Patrick Y
- Weller, Michael
- ORCID
- Wen, Patrick Y
- Weller, Michael
- Lee, Eudocia Quant
- Alexander, Brian M
- Barthel, Floris P
- Batchelor, Tracy T
- Bindra, Ranjit S
- Chang, Susan M
- Chiocca, E Antonio
- Cloughesy, Timothy F
- Galanis, Evanthia
- Gilbert, Mark R
- Hegi, Monika E
- Horbinski, Craig
- Huang, Raymond Y
- Lassman, Andrew B
- Lim, Michael
- Mehta, Minesh P
- Mellinghoff, Ingo K
- Minniti, Giuseppe
- Nathanson, David
- Platten, Michael
- Preusser, Matthias
- Roth, Patrick
- Sanson, Marc
- Schiff, David
- Short, Susan C
- Taphoorn, Martin J B
- Tonn, Joerg-Christian
- Tsang, Jonathan
- Verhaak, Roel G W
- Wick, Wolfgang
- Zadeh, Gelareh
- Reardon, David A
- Aldape, Kenneth D
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-04-24
- Volume
- 22
- Issue
- 8
- Pages
- 1073-1113
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- PMC
- PMC7594557
- OpenAlex
- W3020099303
- Cited by
- 1,168
- References
- 334
- Citations by year
- 2026: 166 · 2025: 215 · 2024: 242 · 2023: 204 · 2022: 194 · 2021: 118 · 2020: 28
- FWCI
- 71.12
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Neuro-Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- SERVAL (Université de Lausanne) (acceptedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion, cc-by-nc)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
- IRIS (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- JuSER (Forschungszentrum Jülich) (submittedVersion)
- LillOA (Université de Lille (University Of Lille)) (submittedVersion)
- The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Funders
- University of Leeds
- National Institutes of Health (UL1TR001863)
- National Cancer Institute (P01CA069246, P30CA008748, P50CA211015, P30CA016672, P01CA163205)
- National Institute of Neurological Disorders and Stroke (R35NS105109)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
- Keywords
- glioblastoma, IDH-wildtype glioblastoma, adult brain tumors, molecular pathogenesis, targeted therapy, DNA damage response, metabolic therapy, immunotherapy, viral therapy, treatment management
- MeSH terms
- Brain Neoplasms, Glioblastoma, Humans, Isocitrate Dehydrogenase, Randomized Controlled Trials as Topic, Clinical Trials, Phase III as Topic, Chemoradiotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
